A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence? | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

A Systematic Review on the Use of Bortezomib in Multiple Myeloma Patients with Renal Impairment: What Is the Published Evidence?

Acta Haematol (2011) 126 (3): 163–168.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Crystalline Light Chain Casts and Hypercalcemia Induced Acute Kidney Injury: A Rare Presentation of Multiple Myeloma

Toshiya Nishigaito
Kensuke Mitsumoto
Rinko Katsunuma
Yuri Hirai
Chikako Yamashita
Aya Mizumoto
Takashi Uzu

Internal Medicine (2024) 63 (12): 1751.

Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study

Parameswaran Hari
Dominick Latremouille-Viau
Peggy Lin
Annie Guerin
Medha Sasane

Medicine (2024) 103 (26): e38609.

Successful renal recovery from multiple myeloma-associated crystalline light chain cast nephropathy and accompanying acute kidney injury with early use of bortezomib-based therapy: a case report and literature review

Kosuke Miki
Yoshinosuke Shimamura
Takuto Maeda
Norihito Moniwa
Yayoi Ogawa
Taku Shimizu
Toshiaki Hayashi
Hajime Sakai
Hideki Takizawa

CEN Case Reports (2022) 12 (1): 56.

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria

Kaladada I. Korubo
Anazoeze J. Madu
Helen C. Okoye
Benedict Nwogoh

Journal of Global Oncology (2018) (4): 1.

Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report

Rio Noto
Nozomu Kamiura
Yuichiro Ono
Sumie Tabata
Shigeo Hara
Hideki Yokoi
Akihiro Yoshimoto
Motoko Yanagita

BMC Nephrology (2017) 18 (1)

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Heinz Ludwig
Hedwig Kasparu
Clemens Leitgeb
Elisabeth Rauch
Werner Linkesch
Niklas Zojer
Richard Greil
Adelheid Seebacher
Ludek Pour
Adalbert Weißmann
Zdeněk Adam

Blood (2014) 123 (7): 985.

Dialysis‐dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma

Philip T Murphy
Cherisse Baldeo
Patrick O'Kelly
Jeremy Sargant
Patrick Thornton
Mary McCloy
Peter Conlon
Colm Magee
Mark Denton
John Quinn

British Journal of Haematology (2014) 165 (6): 890.

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

James R. Berenson
Ori Yellin
Alberto Bessudo
Ralph V. Boccia
Stephen J. Noga
Donald S. Gravenor
Dipti Patel‐Donnelly
Robert S. Siegel
Tarun Kewalramani
Edward J. Gorak
Youram Nassir
Regina A. Swift
Debra Mayo

British Journal of Haematology (2013) 160 (3): 321.

Bortezomib for the Treatment of Previously Untreated Multiple Myeloma

Alessandra Romano
Concetta Conticello
Francesco Di Raimondo

Immunotherapy (2013) 5 (4): 327.